CD8A and cancer: Neoadjuvant chemotherapy was associated with a decrease in intercellular interactions (as predicted by the computational inference of ligand–receptor interactions from single-cell RNA sequencing data), including a reduction in the inhibitory checkpoint molecular expression of CD8+ T cells and cancer cells (TIGIT-PVR signaling), indicating that chemotherapy alters the TME in PDAC [92].